Furthermore, special attention is paid to recent studies investigating the efficacy of hypomethylating agents in PTCL with mutations in epigenetic regulators (e. g., TET2), which have yielded promising results (18, 19) and justified the initiation of further studies. This evidence concerns the gene TET2 and mature T-cell and NK-cell non-Hodgkin lymphoma.